Barclays’s Acorda Therapeutics ACOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-100
| Closed | -$9K | – | 5714 |
|
|
2020
Q2 | $9K | Sell |
100
-222
| -69% | -$23.5K | ﹤0.01% | 5345 |
|
|
2020
Q1 | $36K | Sell |
322
-262
| -45% | -$51.6K | ﹤0.01% | 5408 |
|
|
2019
Q4 | $144K | Buy |
584
+149
| +34% | +$37.6K | ﹤0.01% | 5265 |
|
|
2019
Q3 | $149K | Sell |
435
-124
| -22% | -$67.4K | ﹤0.01% | 5173 |
|
|
2019
Q2 | $513K | Buy |
559
+251
| +81% | +$308K | ﹤0.01% | 4296 |
|
|
2019
Q1 | $491K | Sell |
308
-112
| -27% | -$202K | ﹤0.01% | 4143 |
|
|
2018
Q4 | $786K | Sell |
420
-382
| -48% | -$831K | ﹤0.01% | 3366 |
|
|
2018
Q3 | $1.89M | Buy |
802
+469
| +141% | +$1.45M | ﹤0.01% | 2943 |
|
|
2018
Q2 | $1.15M | Buy |
333
+184
| +123% | +$563K | ﹤0.01% | 3133 |
|
|
2018
Q1 | $425K | Buy |
149
+78
| +110% | +$234K | ﹤0.01% | 4133 |
|
|
2017
Q4 | $183K | Buy |
71
+27
| +61% | +$76.8K | ﹤0.01% | 4762 |
|
|
2017
Q3 | $124K | Sell |
44
-6
| -12% | -$15.8K | ﹤0.01% | 4778 |
|
|
2017
Q2 | $119K | Sell |
50
-738
| -94% | -$1.46M | ﹤0.01% | 4785 |
|
|
2017
Q1 | $1.99M | Buy |
788
+299
| +61% | +$861K | ﹤0.01% | 2104 |
|
|
2016
Q4 | $1.1M | Sell |
489
-307
| -39% | -$730K | ﹤0.01% | 2652 |
|
|
2016
Q3 | $1.99M | Sell |
796
-854
| -52% | -$2.55M | ﹤0.01% | 2005 |
|
|
2016
Q2 | $5.05M | Buy |
1,650
+1,133
| +219% | +$3.68M | 0.01% | 1303 |
|
|
2016
Q1 | $1.61M | Buy |
517
+283
| +121% | +$1.17M | ﹤0.01% | 2119 |
|
|
2015
Q4 | $1.18M | Sell |
234
-2,076
| -90% | -$9.07M | ﹤0.01% | 2465 |
|
|
2015
Q3 | $7.21M | Buy |
2,310
+2,303
| +32,900% | +$8.93M | 0.01% | 1124 |
|
|
2015
Q2 | $29K | Sell |
7
-7
| -50% | -$27K | ﹤0.01% | 5474 |
|
|
2015
Q1 | $58K | Sell |
14
-30
| -68% | -$137K | ﹤0.01% | 5188 |
|
|
2014
Q4 | $212K | Sell |
44
-10
| -19% | -$42.9K | ﹤0.01% | 4585 |
|
|
2014
Q3 | $213K | Sell |
54
-43
| -44% | -$161K | ﹤0.01% | 4696 |
|
|
2014
Q2 | $384K | Buy |
97
+33
| +52% | +$135K | ﹤0.01% | 4226 |
|
|
2014
Q1 | $284K | Sell |
64
-336
| -84% | -$1.36M | ﹤0.01% | 4460 |
|
|
2013
Q4 | $1.39M | Sell |
400
-347
| -46% | -$1.35M | ﹤0.01% | 3036 |
|
|
2013
Q3 | $3.05M | Sell |
747
-14
| -2% | -$60.3K | ﹤0.01% | 2138 |
|
|
2013
Q2 | $3.02M | Buy |
+761
| New | +$3.13M | ﹤0.01% | 2091 |
|
Other funds holding ACOR
GCP
Barclays's ACOR Position: Q3 2020 in Review
Barclays sold out of Acorda Therapeutics (ACOR) in Q3 2020, closing a stake of 100 shares — an estimated $9K sold.
Barclays first reported a position in ACOR in Q2 2013 and held it in 29 quarters. The position peaked at $7.21M in Q3 2015. 60 funds tracked by Wall St. Rank hold ACOR as of Q3 2020.
- Barclays reported no remaining Acorda Therapeutics position as of Q3 2020 after selling out during the quarter.
- Barclays sold 100 Acorda Therapeutics shares in Q3 2020, an estimated $9K.
- Barclays first reported a position in Acorda Therapeutics in Q2 2013 and held it in 29 quarters.
- Barclays's Acorda Therapeutics position peaked at $7.21M in Q3 2015.
- 60 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2020.
Based on Barclays's 13F filing for Q3 2020, filed 12 Nov 2020.